|Last Price$51.42||Day Change (%)-3.64%|
|Open Price$53.37||Day Change ($)-1.94|
|Day Range50.41–53.54||52-Week Range31.25–58.46|
As of Wed 9/28/2016 5:14:00 PM | USD
Global Tourette Syndrome Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Neurocrine Biosciences , Otsuka Holdings, Pfizer - Research and Markets
On Monday, Neurocrine Biosciences NBIX accelerated its anticipated filing date for indiplon capsules to the second quarter of 2007 instead of 2009. We're placing Neurocrine under review while we revisit our assumptions, and because DOV Pharmaceutical DOVP is entitled to a royalty on any indiplon ...